Vernalis is a UK-based specialty bio-pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
Frova® is a selective 5-HT1B/1D receptor agonist approved in the United States and Europe as an acute oral treatment for migraine headache.
Distinctive Characteristics
.
To find out more details of the conditions we are seeking to treat: view our product pipeline.